Why I’d Buy Hikma Pharmaceuticals Plc, Hold Shire plc & Sell AstraZeneca plc

Hikma Pharmaceuticals Plc (LON:HIK), Shire plc (LON:SHP) and AstraZeneca plc (LON: AZN) are very different investment propositions, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recent market sell-off just reinforces my view on Hikma (LSE: HIK), Shire (LSE: SHP)  and AstraZeneca (LSE: AZN).

So, what should you do with them right now?

Two Scenarios

Their shares carry very different risk profiles, and there are two investment strategies here. 

To keep scenario A as simple as possible, I’d structure a portfolio in which all my savings are split among these three shares by giving them an equal weight — the same British pound value for each stock. 

This way, I’d achieve a properly balanced low-beta investment portfolio of 0.9 that should outperform the FTSE 100 if the market turns south. But I do not fancy Astra, and Hikma’s growth rate is truly appealing.

Excluding a different weight for each stock in the investment portfolio, then the only possible scenario B is to choose one single stock and pull the trigger.

Which one, though? 

M&A risk at Shire

Shire is the best of all based on fundamentals, but its stock carries more risk now than at any given time this year. Its latest deal-making ambitions will be debated for months, and Baxalta could be a pricey target — there is a significant risk that we have to pay over the odds for its short-term prospects. 

Shire stock trades on a forward earnings multiple of 28x, which represents a big premium against the market. Consider that the long-term average P/E of the FTSE 100 is 15, which is not far away from the main index’s current valuation. That said, the average level of operating profitability for the index’s constituents is several percentage points lower than that of Shire, while its dividends are expected to rise at 10%-20% a year. 

Shire beats both the market and Astra, which is not a valid alternative, I’d say — but Hikma is more attractive!

Hikma vs Astra: an obvious call!

Hikma’s growth prospects have become even more enticing following its acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane for $2.65bn. 

Its beta is the highest in the peer group and its shares trade on forward net earnings multiples that are a bit lower than those of Shire. 

Hikma’s equity value is about 20% that of Shire and 10% of Astra’s, but is set to grow at a very fast pace if management keep up the good work it has done in recent years. Its capital allocation strategy makes a lot of sense, and has contributed to a two-year performance that reads +125%.

In spite of recent volatility, Hikma has fallen only 2% over the last month of trade, having outperformed Astra by one percentage point and Shire by nine percentage points. These trends could well last until the end of 2015 and beyond.

Finally, the problem with Astra is that we know its long-term growth projections, but we don’t know how Astra will achieve its ambitions goals. 

The most mature business of the three, Astra is an obvious play either for investors who believe that a change of ownership will materialise or for those who are interested in the sector and consider its beta, at 0.6, a good sign of a lower level of risk. 

Well, I wouldn’t bet on that based on its trading multiple of 32x forward earnings. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Down 70%+ since 2020, is IAG’s share price an unmissable bargain?

IAG’s share price is still down around 73% from its pre-Covid level, but with the business performing well last year,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£17,000 of shares in the FTSE 100 dividend giant can make me £18,874 every year in passive income!

This FTSE 100 dividend superstar has an 8.8% yield with dividends projected to rise. It looks very undervalued to me…

Read more »

Investing Articles

2 top UK growth stocks I’m buying for my Stocks and Shares ISA in July

Looking for UK-listed growth firms to add to a Stocks and Shares ISA? Our writer highlights two he's planning to…

Read more »

artificial intelligence investing algorithms
Investing Articles

This overvalued growth stock makes Nvidia look cheap!

ARM Holdings is a growth stock that’s benefitted from the AI rally. Muhammad Cheema takes a look at whether this…

Read more »

Investing Articles

1 penny stock I’d buy today while it’s 63p

This penny stock's down 70% since last March, yet could be set for a big comeback as the firm rebuilds…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »